Buprenorphine and its formulations: a comprehensive review
Buprenorphine, a novel long-acting analgesic, was developed with the intention of two purposes: analgesia and opioid use disorder. Regarding its pharmacodynamics, it is a partial agonist at mu receptors, an inverse agonist at kappa receptors, and an antagonist at delta receptors. For the purpose of analgesia, three formulations of buprenorphine were developed: IV/IM injectable formulation (Buprenex®), transdermal patch formulation (Butrans®), and buccal film formulation (Belbuca®). Related to opioid dependence, the formulations developed were subcutaneous extended release (Sublocade®), subdermal implant (Probuphine®), and sublingual tablets (Subutex®). Lastly, in order to avoid misuse of buprenorphine for opioid dependence, two combination formulations paired with naloxone were developed: film formulation (Suboxone®) and tablet formulation (Zubsolv®). In this review, we present details of each formulation along with their similarities and differences between each other and clinical considerations.
1. Urits I, Pham C, Swanson D, et al. The utilization of buprenorphine in chronic pain. Best Practice & Research Clinical Anaesthesiology.2020;34(3):355-368. doi:10.1016/j.bpa.2020.06.005
2. Diversion Control Division D. BUPRENORPHINE (Trade Names: Buprenex®, Suboxone®, Subutex®); 2019.
3. Davis MP, Pasternak G, Behm B. Treating Chronic Pain: An Overview of Clinical Studies Centered on the Buprenorphine Option. Drugs.2018;78(12):1211-1228. doi:10.1007/s40265-018-0953-z
4. Urits I, Viswanath O, Petro J, Yazdi C. Building a Bridge Between Primary and Perioperative Care: Addressing the Challenges of Perioperative Buprenorphine Maintenance and Postdischarge Therapy. Ochsner Journal.
2018;18(4):305-307. doi:10.31486/toj.18.0146
5. Shulman M, Wai JM, Nunes EV. Buprenorphine Treatment for Opioid Use Disorder: An Overview. CNS Drugs.
2019;33(6):567-580. doi:10.1007/s40263-019-00637-z
6. Gress K, Charipova K, Jung JW, et al. A comprehensive review of partial opioid agonists for the treatment of chronic pain. Best Practice & Research Clinical Anaesthesiology.2020;34(3):449-461. doi:10.1016/j.bpa.2020.06.003
7. Webster L, Gudin J, Raffa RB, et al. Understanding Buprenorphine for Use in Chronic Pain: Expert Opinion. Pain Medicine.2020;21(4):714-723. doi:10.1093/pm/pnz356
8. Kenney SR, Anderson BJ, Bailey GL, Stein MD. Buprenorphine Treatment Formulations: Preferences among Persons in Opioid Withdrawal Management. J Subst Abuse Treat.2018;94(55):55-59. doi:10.1016/j.jsat.2018.08.011
9. Schmidt-Hansen M, Bromham N, Taubert M, Arnold S, Hilgart JS. Buprenorphine for treating cancer pain. Cochrane Database of Systematic Reviews.2015;2015(3). doi:10.1002/14651858.cd009596.pub4
10. FDA. BUPRENEX® (buprenorphine hydrochloride) injection.
11. Urman RD, Jonan AB, Kaye AD. Buprenorphine Formulations: Clinical Best Practice Strategies Recommendations for Perioperative Management of Patients Undergoing Surgical or Interventional Pain Procedures.
12. Hale M, Garofoli M, Raffa RB. Benefit-Risk Analysis of Buprenorphine for Pain Management. Journal of Pain Research.2021;14:1359-1369. doi:10.2147/jpr.s305146
13. Trescot AM, Datta S, Lee M, Hansen H. Opioid Pharmacology.
14. Pergolizzi JV Jr, Raffa RB. Safety And Efficacy Of The Unique Opioid Buprenorphine For The Treatment Of Chronic Pain. Journal of Pain Research.2019;12:3299-3317. doi:10.2147/jpr.s231948
15. FDA. BUTRANS®.
16. Aiyer R, Gulati A, Gungor S, Bhatia A, Mehta N. Treatment of chronic pain with various buprenorphine formulations: A systematic review of clinical studies. Anesthesia & Analgesia.2018;127(2):529-538. doi:10.1213/ane.0000000000002718
17. Sorge J, Sittl R. Transdermal buprenorphine in the treatment of chronic pain: results of a phase III, multicenter, randomized, double-blind, placebo-controlled study. Clin Ther.2004;26(11):1808-1820. doi:10.1016/j.clinthera.2004.11.008
18. Mitra F, Chowdhury S, Shelley M, Williams G. A feasibility study of transdermal buprenorphine versus transdermal fentanyl in the long-term management of persistent non-cancer pain. Pain Med.2013;14(1):75-83. doi:10.1111/pme.12011
19. Pergolizzi JV Jr, Magnusson P, LeQuang JA, et al. Transdermal Buprenorphine for Acute Pain in the Clinical Setting: A Narrative Review. Journal of Pain Research.2021;14:871-879. doi:10.2147/jpr.s280572
20. Londhe S, Patwardhan M, Shah R, Oak M. Efficacy and Safety of Buprenorphine Transdermal Patch for Immediate Postoperative Analgesia After Total Knee Arthroplasty Surgery. J Arthroplasty.
2020;35(6S):S178-S181. doi:10.1016/j.arth.2020.02.015
21. Dalal S, Chitmeni A, Berger AA, et al. Buprenorphine for Chronic Pain: A Safer Alternative to Traditional Opioids. Health Psychology Research.2021;9(1). doi:10.52965/001c.27241
22. FDA. BELBUCA (buprenorphine) Buccal Film. Accessed March 30, 2022.https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207932Orig1s000TOC.cfm
23. Gudin J, Fudin J. A Narrative Pharmacological Review of Buprenorphine: A Unique Opioid for the Treatment of Chronic Pain. Pain and Therapy.2019;9. doi:10.6084/m9.figshare.11353028
24. Hale M, Gimbel J, Rauck R. Buprenorphine buccal film for chronic pain management. Pain Management.
2020;10(4):213-223. doi:10.2217/pmt-2020-0013
25. Gimbel J, Spierings ELH, Katz N, Xiang Q, Tzanis E, Finn A. Efficacy and tolerability of buccal buprenorphine in opioid-experienced patients with moderate to severe chronic low back pain: results of a phase 3, enriched enrollment, randomized withdrawal study. Pain.2016;157(11):2517-2526. doi:10.1097/j.pain.0000000000000670
26. Hale M, Urdaneta V, Kirby T, Xiang Q, Rauck R. Long-term safety and analgesic efficacy of buprenorphine buccal film in patients with moderate-to-severe chronic pain requiring around-the-clock opioids. J Pain Res.
2017;10:233-240. doi:10.2147/jpr.s120170
27. Rauck RL, Potts J, Xiang Q, Tzanis E, Finn A. Efficacy and tolerability of buccal buprenorphine in opioid-naive patients with moderate to severe chronic low back pain. Postgrad Med.2016;128(1):1-11. doi:10.1080/00325481.2016.1128307
28. Steiner D, Munera C, Hale M, Ripa S, Landau C. Efficacy and safety of buprenorphine transdermal system (BTDS) for chronic moderate to severe low back pain: a randomized, double-blind study. J Pain.
2011;12(11):1163-1173. doi:10.1016/j.jpain.2011.06.003
29. FDA. Sublocade Drug Label; 2021.https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/209819s018lbl.pdf#page=45
30. Pecoraro A, Fishman M, Ma M, Piralishvili G, Woody GE. Pharmacologically assisted treatment of opioid-dependent youth. Paediatr Drugs.2013;15(6):449-458. doi:10.1007/s40272-013-0041-5
31. Fareed A, Eilender P, Ketchen B, et al. Factors affecting noncompliance with buprenorphine maintenance treatment. Journal of Addiction Medicine.2014;8(5):345-350. doi:10.1097/adm.0000000000000057
32. Somaini L, Vecchio S, Corte C, et al. Prolonged-Release Buprenorphine Therapy in Opioid Use Disorder Can Address Stigma and Improve Patient Quality of Life. Cureus.2021;13(10):e18513. doi:10.7759/cureus.18513
33. Winstock AR, Lea T, Sheridan J. Prevalence of diversion and injection of methadone and buprenorphine among clients receiving opioid treatment at community pharmacies in New South Wales, Australia. Int J Drug Policy.2008;19(6):450-458. doi:10.1016/j.drugpo.2007.03.002
34. Lofwall MR, Walsh SL, Nunes EV, et al. Weekly and monthly subcutaneous buprenorphine depot formulations vs daily sublingual buprenorphine with naloxone for treatment of opioid use disorder: a randomized clinical trial. JAMA Intern Med.2018;178(6):764. doi:10.1001/jamainternmed.2018.1052
35. Ling W, Shoptaw S, Goodman-Meza D. Depot Buprenorphine Injection In The Management Of Opioid Use Disorder: From Development To Implementation. Substance Abuse and Rehabilitation.
2019;10(69):69-78. doi:10.2147/sar.s155843
36. Nasser AF, Greenwald MK, Vince B, et al. Sustained-Release Buprenorphine (RBP-6000) Blocks the Effects of Opioid Challenge With Hydromorphone in Subjects With Opioid Use Disorder. J Clin Psychopharmacol.
2016;36(1):18-26. doi:10.1097/jcp.0000000000000434
37. Laffont CM, Gomeni R, Heidbreder C, Jones JP III, Nasser AF. Population Pharmacokinetic Modeling After Repeated Administrations of RBP-6000, a New, Subcutaneously Injectable, Long-Acting, Sustained-Release Formulation of Buprenorphine, for the Treatment of Opioid Use Disorder. J Clin Pharmacol.
2016;56(7):806-815. doi:10.1002/jcph.665
38. Rolland B, Trojak B, Nourredine M, et al. Determinants of interest in extended-released buprenorphine: A survey among 366 French patients treated with buprenorphine or methadone. Drug and Alcohol Dependence.
2021;220:108492. doi:10.1016/j.drugalcdep.2020.108492
39. Neale J, Tompkins CNE, Strang J. Prolonged-release opioid agonist therapy: qualitative study exploring patients' views of 1-week, 1-month, and 6-month buprenorphine formulations. Harm Reduct J.
2019;16(1). doi:10.1186/s12954-019-0296-4
40. Gilman M, Li L, Hudson K, et al. Current and future options for opioid use disorder: a survey assessing real-world opinion of service users on novel therapies including depot formulations of buprenorphine. Patient Prefer Adherence.2018;12:2123-2129. doi:10.2147/ppa.s180641
41. Woods JS, Joseph H. Stigma from the Viewpoint of the Patient. J Addict Dis.2015;34(2-3):238-247. doi:10.1080/10550887.2015.1059714
42. Larance B, Degenhardt L, Grebely J, et al. Perceptions of extended-release buprenorphine injections for opioid use disorder among people who regularly use opioids in Australia. Addiction (Abingdon, England).
2020;115(7):1295-1305. doi:10.1111/add.14941
43. Kenney SR, Anderson BJ, Bailey GL, Stein MD. Buprenorphine Treatment Formulations: Preferences among Persons in Opioid Withdrawal Management. J Subst Abuse Treat.2018;94(55):55-59. doi:10.1016/j.jsat.2018.08.011
44. Neale J, Tompkins CNE, Strang J. Depot buprenorphine injections for opioid use disorder: Patient information needs and preferences. Drug Alcohol Rev.2019;38(5):510-518. doi:10.1111/dar.12939
45. Neale J, Tompkins CNE, McDonald R, Strang J. Implants and depot injections for treating opioid dependence: Qualitative study of people who use or have used heroin. Drug Alcohol Depend.
2018;189:1-7. doi:10.1016/j.drugalcdep.2018.03.057
46. FDA. FDA Probuphine Drug Label; 2016.https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/204442s009lbl.pdf#page=49
47. White J, Bell J, Saunders JB, et al. Open-label dose-finding trial of buprenorphine implants (Probuphine)® for treatment of heroin dependence. Drug and Alcohol Dependence.2009;103(1-2):37-43. doi:10.1016/j.drugalcdep.2009.03.008
48. Kleppner SR, Patel R, Costantini LC, McDonough J. In-vitro and in-vivo characterization of a buprenorphine delivery system. J Pharm Pharmacol.2006;58(3):295-302. doi:10.1211/jpp.58.3.0002
49. Woody GE, Metzger DS. Injectable extended-release naltrexone for opioid dependence. Lancet.
2011;378(9792):664-665. doi:10.1016/s0140-6736(11)61330-5
50. Barnwal P, Das S, Mondal S, Ramasamy A, Maiti T, Saha A. Probuphine® (buprenorphine implant): a promising candidate in opioid dependence. Ther Adv Psychopharmacol.2017;7(3):119-134. doi:10.1177/2045125316681984
51. Rosenthal RN. Novel Formulations of Buprenorphine for Treatment of Opioid Use Disorder. Focus (Am Psychiatr Publ).2019;17(2):104-109. doi:10.1176/appi.focus.20180043
52. Lopatko OV, White JM, Huber A, Ling W. Opioid effects and opioid withdrawal during a 24 h dosing interval in patients maintained on buprenorphine. Drug Alcohol Depend.2003;69(3):317-322. doi:10.1016/s0376-8716(02)00322-8
53. Rosenthal RN, Lofwall MR, Kim S, et al. Effect of Buprenorphine Implants on Illicit Opioid Use Among Abstinent Adults With Opioid Dependence Treated With Sublingual Buprenorphine: A Randomized Clinical Trial. JAMA.2016;316(3):282-290. doi:10.1001/jama.2016.9382
54. Borodovsky JT, Levy S, Fishman M, Marsch LA. Buprenorphine treatment for adolescents and young adults with opioid use disorders: a narrative review. J Addict Med.2018;12(3):170-183. doi:10.1097/adm.0000000000000388
55. Marsch LA, Moore SK, Borodovsky JT, et al. A randomized controlled trial of buprenorphine taper duration among opioid-dependent adolescents and young adults. Addiction (Abingdon, England).2016;111(8):1406-1415. doi:10.1111/add.13363
56. FDA. Subutex Drug Label. https://www.accessdata.fda.gov
57. Weiss RD, Potter JS, Griffin ML, et al. Long-term outcomes from the National Drug Abuse Treatment Clinical Trials Network Prescription Opioid Addiction Treatment Study. Drug Alcohol Depend.2015;150:112-119. doi:10.1016/j.drugalcdep.2015.02.030
58. Sigmon SC, Dunn KE, Saulsgiver K, et al. A randomized, double-blind evaluation of buprenorphine taper duration in primary prescription opioid abusers. JAMA Psychiatry.2013;70(12):1347-1354. doi:10.1001/jamapsychiatry.2013.2216
59. Weiss RD, Potter JS, Fiellin DA, et al. Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence: a 2-phase randomized controlled trial. Arch Gen Psychiatry.2011;68(12):1238-1246. doi:10.1001/archgenpsychiatry.2011.121
60. Elkader A, Sproule B. Buprenorphine: clinical pharmacokinetics in the treatment of opioid dependence. Clin Pharmacokinet.2005;44(7):661-680. doi:10.2165/00003088-200544070-00001
61. Lewis JW. Buprenorphine. Drug Alcohol Depend.1985;14(3-4):363-372. doi:10.1016/0376-8716(85)90067-5
62. Mattick RP, Breen C, Kimber J, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev.2014;2014(2). doi:10.1002/14651858.cd002207.pub4
63. Yokell MA, Zaller ND, Green TC, Rich JD. Buprenorphine and Buprenorphine/Naloxone Diversion, Misuse, and Illicit Use: An International Review. Curr Drug Abuse Rev.2011;4(1):28-41. doi:10.2174/1874473711104010028
64. Lavonas EJ, Severtson SG, Martinez EM, et al. Abuse and diversion of buprenorphine sublingual tablets and film. J Subst Abuse Treat.2014;47(1):27-34. doi:10.1016/j.jsat.2014.02.003
65. Lofwall MR, Martin J, Tierney M, Fatséas M, Auriacombe M, Lintzeris N. Buprenorphine diversion and misuse in outpatient practice. Journal of Addiction Medicine.2014;8(5):327-332. doi:10.1097/adm.0000000000000029
66. Lofwall MR, Walsh SL. A review of buprenorphine diversion and misuse: the current evidence base and experiences from around the world. J Addict Med.2014;8(5):315-326. doi:10.1097/adm.0000000000000045
67. Middleton LS, Nuzzo PA, Lofwall MR, Moody DE, Walsh SL. The pharmacodynamic and pharmacokinetic profile of intranasal crushed buprenorphine and buprenorphine/naloxone tablets in opioid abusers. Addiction (Abingdon, England).2011;106(8):1460-1473. doi:10.1111/j.1360-0443.2011.03424.x
68. Degenhardt L, Larance BK, Bell JR, et al. Injection of medications used in opioid substitution treatment in Australia after the introduction of a mixed partial agonist-antagonist formulation. Med J Aust.
2009;191(3):161-165. doi:10.5694/j.1326-5377.2009.tb02729.x
69. Simojoki K, Alho H. Five-year follow-up of buprenorphine abuse potential. Journal of Alcohol and Drug Dependence.2013;1:1-6.
70. Boyer EW, McCance-Katz EF, Marcus S. Methadone and buprenorphine toxicity in children. Am J Addict.
2010;19(1):89-95. doi:10.1111/j.1521-0391.2009.00002.x
71. Farnaghi F, Gholami N, Hassanian-Moghaddam H, McDonald R, Zamanzadeh R, Zamani N. Unintentional buprenorphine and methadone poisoning in children: a matched observational study. Clinical Toxicology.
2021;59(8):727-733. doi:10.1080/15563650.2020.1869755
72. C. Martin T, Rocque M. Accidental and non-accidental ingestion of methadone and buprenorphine in childhood: a single center experience, 1999-2009. Curr Drug Saf.2011;6(1):12-16. doi:10.2174/157488611794480034
73. Barnwal P, Das S, Mondal S, Ramasamy A, Maiti T, Saha A. Probuphine® (buprenorphine implant): a promising candidate in opioid dependence. Therapeutic Advances in Psychopharmacology.
2017;7(3):119-134. doi:10.1177/2045125316681984
74. fda, cder. HIGHLIGHTS OF PRESCRIBING INFORMATION.
75. Prescribing Information | SUBOXONE (buprenorphine and naloxone) Sublingual Film (CIII); 2021.
76. 455-14 HIGHLIGHTS OF PRESCRIBING INFORMATION.
77. Buprenorphine | SAMHSA. Accessed April 18, 2022. https://www.samhsa.gov/medication-assisted-treatment/medications-counseling-related-condition s/buprenorphine
78. Lintzeris N, Leung SY, Dunlop AJ, et al. A randomised controlled trial of sublingual buprenorphine-naloxone film versus tablets in the management of opioid dependence. Drug Alcohol Depend.
2013;131(1-2):119-126. doi:10.1016/j.drugalcdep.2012.12.009
79. Fudala PJ, Bridge TP, Herbert S, et al. Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. N Engl J Med.2003;349(10):949-958. doi:10.1056/nejmoa022164
80. Gunderson EW, Hjelmstrom P, Sumner M. Effects of a higher-bioavailability buprenorphine/naloxone sublingual tablet versus buprenorphine/naloxone film for the treatment of opioid dependence during induction and stabilization: a multicenter, randomized trial. Clin Ther.2015;37(10):2244-2255. doi:10.1016/j.clinthera.2015.08.025
81. Roux P, Sullivan MA, Cohen J, et al. Buprenorphine/naloxone as a promising therapeutic option for opioid abusing patients with chronic pain: reduction of pain, opioid withdrawal symptoms, and abuse liability of oral oxycodone. Pain.2013;154(8):1442-1448. doi:10.1016/j.pain.2013.05.004
82. Jonsson M, Mundin G, Sumner M. Pharmacokinetic and pharmaceutical properties of a novel buprenorphine/naloxone sublingual tablet for opioid substitution therapy versus conventional buprenorphine/naloxone sublingual tablet in healthy volunteers. Eur J Pharm Sci.2018;122:125-133. doi:10.1016/j.ejps.2018.06.024